KCNT1-Related Epilepsy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which KCNT1-Related Epilepsy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1/2

NCT07227857

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopath…

Study CL1-230815-001 (KANDLE) is a Phase Ib/II, First In Human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharm…

United States20 participantsStarted 2025-11-24

Treatment: S230815- Starting dose A, S230815- Dose B

RecruitingPhase 1

NCT07156201

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in…

This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted d…

Australia74 participantsStarted 2025-08-28

Treatment: ABS-1230, Placebo

All recent trials (3 shown)

CompletedNot Applicable

NCT04924153

A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epi…

The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head gr…

United States35 participantsStarted 2021-08-17

Treatment: No Intervention